VIVOZON PHARMACEUTICAL CO., LTD.
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
082800 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단2길 34-40, 화성시
- Website:
- https://www.vivozon.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Vivozon Pharmaceutical Co., Ltd. is a global drug development company established in 2008, focused on creating innovative treatments for pain and central nervous system (CNS) diseases. The company's core research centers on a multi-target drug discovery platform designed to develop chemical drugs with synergistic efficacy. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic. Vivozon utilizes an efficacy-based screening system from the early stages of discovery to advance its pipeline, which also targets conditions such as depression, substance use disorders, and neurodegenerative diseases.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for VIVOZON PHARMACEUTICAL CO., LTD. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all VIVOZON PHARMACEUTICAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for VIVOZON PHARMACEUTICAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
